Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine

@article{Elsas2001ElucidatingTA,
  title={Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine},
  author={Andrea van Elsas and Roger P. M. Sutmuller and Arthur A. Hurwitz and Jennifer Ziskin and Jennifer Villasenor and Jan-Paul Medema and Willem W. Overwijk and Nicholas P Restifo and Cornelis J M Melief and Rienk Offringa and James P Allison},
  journal={The Journal of Experimental Medicine},
  year={2001},
  volume={194},
  pages={481 - 490}
}
We have previously shown that small B16 melanomas can be successfully treated using a combination of anti-cytotoxic T lymphocyte antigen (CTLA)-4 monoclonal antibody with a granulocyte/macrophage colony-stimulating factor (GM-CSF) producing irradiated tumor cell vaccine. Regression of tumors results in long-lasting immunity and is frequently accompanied by autoimmune depigmentation. Here we examine the cellular and molecular mechanisms of this combined treatment. Histological examination of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 93 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 40 references

Design and evaluation of antigen-specific vaccination strategies against cancer

  • R. Offringa, S. H. van der Burg, F. Ossendorp, R. E. Toes, C. J. Melief
  • Curr. Opin. Immunol
  • 2000

Similar Papers

Loading similar papers…